KKI04 / AIIMS - LARVOL DELTA

Design, Synthesis and Assessment of Novel Molecule against Drug-Resistant Dual Mutant EGFR (T790M/L858R) to Treat NSCLC (IASLC-WCLC 2023) - " Molecule KKI04, has shown potential inhibition activity against the drug-resistant EGFR kinases compared to Osimertinib, a third-generation EGFR_TKI. The designed molecule, KKI04, has shown promising activity at the molecular and cellular level against drug-resistant dual mutant T/L EGFR kinase. KKI04 has shown superior inhibition activity compared to all existing EGFR kinase inhibitors. However, this molecule should be further studied on in-vivo mice xenografts to evaluate its tumour-reducing and clinical translatable ability, which are in progress."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ANXA5 • EGFR